AXOVANT GENE THERAPIES LTD - COM (AXGT)

CUSIP: G0750W203

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class
Equity / COM
Total 13F shares
11,936,862
Share change
+309,255
Total reported value
$33,658,003
Put/Call ratio
168%
Price per share
$2.82
Number of holders
32
Value change
+$976,428
Number of buys
16
Number of sells
14

Quarterly Holders Quick Answers

What is CUSIP G0750W203?
CUSIP G0750W203 identifies AXGT - AXOVANT GENE THERAPIES LTD - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AXOVANT GENE THERAPIES LTD - COM (AXGT) as of Q2 2020

As of 30 Jun 2020, AXOVANT GENE THERAPIES LTD - COM (AXGT) was held by 32 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 11,936,862 shares. The largest 10 holders included Consonance Capital Management LP, SPHERA FUNDS MANAGEMENT LTD., Hudson Bay Capital Management LP, DAFNA Capital Management LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Rubric Capital Management LP, Ikarian Capital, LLC, D. E. Shaw & Co., Inc., and GEODE CAPITAL MANAGEMENT, LLC. This page lists 32 institutional shareholders reporting positions in this security for the Q2 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.